A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 35
Healthy Volunteers: t
View:

• Must be over 35 years of age and present with gradual progression of PSP-related symtoms

• Must have an informant or study partner that can provide independent information of functioning.

• Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.

Locations
United States
Minnesota
Mayo Clinic
RECRUITING
Rochester
Contact Information
Primary
Sarah M Boland, CCRP
boland.sarah@mayo.edu
507-284-3863
Time Frame
Start Date: 2015-11
Estimated Completion Date: 2025-11
Participants
Target number of participants: 332
Treatments
Experimental: Tau PET Scan, F-18 AV 1451
All subjects will received a Tau PET scan.
Sponsors
Leads: Mayo Clinic

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.